Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Belatacept is an experimental medication shown in clinical trials to have immune system
suppression properties in people who have had renal (e.g., kidney) transplants. This study
will determine whether a combination of anti-rejection drugs, including belatacept, can
prevent the rejection of a first-time, non-human leukocyte antigen (HLA) identical renal
transplant and allow patients to be safely withdrawn from anti-rejection therapy one year
post-transplant.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)